Hancock Whitney Corp Sells 62 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hancock Whitney Corp reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 5,139 shares of the biotechnology company’s stock after selling 62 shares during the period. Hancock Whitney Corp’s holdings in United Therapeutics were worth $1,842,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of UTHR. Renaissance Technologies LLC lifted its position in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the last quarter. LSV Asset Management lifted its holdings in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the period. Pacer Advisors Inc. grew its stake in United Therapeutics by 0.9% in the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after acquiring an additional 4,869 shares in the last quarter. Finally, Swedbank AB purchased a new position in shares of United Therapeutics during the first quarter worth approximately $97,316,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. This trade represents a 74.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 117,227 shares of company stock valued at $43,671,320 in the last three months. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Down 1.1 %

Shares of United Therapeutics stock opened at $368.66 on Tuesday. The firm has a market capitalization of $16.46 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm’s 50 day moving average is $365.54 and its two-hundred day moving average is $333.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the business earned $5.38 EPS. As a group, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. Bank of America lowered their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. The Goldman Sachs Group raised their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.